S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:SYN

Synthetic Biologics Stock Forecast, Price & News

$0.31
+0.00 (+0.03 %)
(As of 10/29/2020 04:59 PM ET)
Add
Compare
Today's Range
$0.30
Now: $0.31
$0.32
50-Day Range
$0.31
MA: $0.41
$0.55
52-Week Range
$0.25
Now: $0.31
$0.75
Volume407,450 shs
Average Volume494,858 shs
Market Capitalization$6.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYN
CUSIPN/A
Phone301 417 4364
Employees11

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$6.03 million
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
$0.31
+0.00 (+0.03 %)
(As of 10/29/2020 04:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Synthetic Biologics (NASDAQ:SYN) Frequently Asked Questions

How has Synthetic Biologics' stock price been impacted by Coronavirus?

Synthetic Biologics' stock was trading at $0.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SYN shares have decreased by 13.8% and is now trading at $0.3102.
View which stocks have been most impacted by COVID-19
.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Synthetic Biologics
.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc. (NASDAQ:SYN) posted its earnings results on Thursday, August, 6th. The company reported ($0.18) earnings per share (EPS) for the quarter.
View Synthetic Biologics' earnings history
.

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Amarin (AMRN), Vaxart (VXRT), Crispr Therapeutics (CRSP), Occidental Petroleum (OXY), Altimmune (ALT), ImmunoGen (IMGN), Micron Technology (MU), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV) and Verastem (VSTM).

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:
  • Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 59, Pay $989.81k)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Vince Wacher, Head of Product and Corp. Devel.
  • Dr. Michael Kaleko, Sr. VP of R&D
  • Ms. Lara M. Guzman, Sr. Director of Project Operations

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the NASDAQ under the ticker symbol "SYN."

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.31.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $6.03 million. Synthetic Biologics employs 11 workers across the globe.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

How can I contact Synthetic Biologics?

The company can be reached via phone at 301 417 4364.

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.